Initial studies had shown a pharmacodynamic effect as early as 24 hours after the first dose of motesanib [20], but the earliest evaluation of PLGF in the phase 3 NSCLC studies was after 3 weeks of treatment (a time point selected prior to formation of the biomarker hypothesis, at the time of study design). The gene discussed is PGF; the disease is non-small cell lung carcinoma.